A Study of MVA85A in Healthy Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

2,797

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

October 31, 2012

Conditions
Tuberculosis
Interventions
BIOLOGICAL

MVA85A/AERAS-485

Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10\^8 pfu.

BIOLOGICAL

Candida Skin Test Antigen

1 test, administered once as a placebo control.

Trial Locations (3)

6705

South African Tuberculosis Vaccine Initiative (Satellite), Robertson

6835

South African Tuberculosis Vaccine Initiative (Satellite), Ceres

6850

South African Tuberculosis Vaccine Initiative (Headquarters), Worcester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University of Oxford

OTHER

collaborator

University of Cape Town

OTHER

lead

Aeras

OTHER